IRON TRIANGLE PARTNERS LP
Q4 2024 Form 13-F

COS COB, CONNECTICUT
CIK 0001779763 · CRD 302077 · SEC-registered investment adviser
$908.4M Reported Value Total

IRON TRIANGLE PARTNERS LP reports 7 total accounts under management (AUM). There are 7 discretionary accounts valued at $1,263,073,089, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
2 funds · $359.6M gross asset value
Hedge Fund: $359.6M
Source: Form ADV filed 2026-03-24
Reported value
$908.4M
Quarter over quarter
+3.7%
Holdings
22
Top-10 concentration
60.2%

Key People

Form ADV owners & control persons
Kevin Thomas Molloy
LIMITED PARTNER
Michael John O'Brien
CHIEF OPERATING OFFICER, CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q4 2024 13F record

Q4 2024 13F filing summary

Q4 2024 Form 13F portfolio summary
Period of report December 31, 2024
Filed February 14, 2025
Form 13F-HR
Reported value $908.4M
Positions 22
Change in reported value +25.9%
New positions 13
Exited positions 15
Position turnover 75.7%
Top-10 concentration 60.2%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q4 2025 13F
Filed Feb 17, 2026
27 $874.7M
Q3 2025 13F
Filed Nov 14, 2025
25 $703.3M
Q2 2025 13F
Filed Aug 14, 2025
26 $651.2M
Q1 2025 13F
Filed May 15, 2025
27 $634.4M
Q4 2024 13F
Filed Feb 14, 2025
22 $908.4M
Q3 2024 13F
Filed Nov 14, 2024
24 $721.8M
Q2 2024 13F
Filed Aug 14, 2024
24 $983.7M
Q1 2024 13F
Filed May 15, 2024
28 $976.3M
Q4 2023 13F
Filed Feb 14, 2024
26 $772.9M
Q3 2023 13F
Filed Nov 14, 2023
23 $684.2M
Q2 2023 13F
Filed Aug 14, 2023
22 $748.1M
Q1 2023 13F
Filed May 15, 2023
27 $693.2M
Q4 2022 13F
Filed Feb 14, 2023
26 $557.8M
Q3 2022 13F
Filed Nov 14, 2022
27 $572.0M
Q2 2022 13F
Filed Aug 15, 2022
24 $771.2M
Q1 2022 13F
Filed May 16, 2022
28 $840.7M
Q4 2021 13F
Filed Feb 14, 2022
25 $717.7M
Q3 2021 13F
Filed Nov 15, 2021
26 $696.8M
Q2 2021 13F
Filed Aug 16, 2021
26 $970.8M
Q1 2021 13F
Filed May 17, 2021
27 $786.5M

5 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q4 2024

Largest Q4 2024 13F positions by reported value
# Holding Reported value % of portfolio
1 A AGILENT TECHNOLOGIES INC $80.1M 8.82%
2 GMED GLOBUS MED INC $69.8M 7.68%
3 ABBV ABBVIE INC $66.5M 7.32%
4 UNH UNITEDHEALTH GROUP INC $61.1M 6.72%
5 UNH C UNITEDHEALTH GROUP INC $50.6M 5.57%
6 TEVA TEVA PHARMACEUTICAL INDS LTD $48.5M 5.34%
7 BSX BOSTON SCIENTIFIC CORP $44.2M 4.87%
8 NBIX NEUROCRINE BIOSCIENCES INC $43.4M 4.78%
9 NVST ENVISTA HOLDINGS CORPORATION $42.4M 4.67%
10 PODD INSULET CORP $40.2M 4.43%
11 MMSI MERIT MED SYS INC $39.4M 4.33%
12 ISRG INTUITIVE SURGICAL INC $39.1M 4.31%
13 DVA DAVITA INC $38.9M 4.29%
14 EXAS EXACT SCIENCES CORP $33.7M 3.71%
15 HQY HEALTHEQUITY INC $32.2M 3.54%
16 MEDP MEDPACE HLDGS INC $29.9M 3.29%
17 TWST TWIST BIOSCIENCE CORP $22.9M 2.52%
18 XBI SPDR SER TR $22.5M 2.48%
19 GKOS GLAUKOS CORP $22.5M 2.48%
20 CAH CARDINAL HEALTH INC $22.0M 2.42%

Values as reported on the Q4 2024 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings